Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Journal Article


Authors: Döhner, H.; Estey, E.; Grimwade, D.; Amadori, S.; Appelbaum, F. R.; Büchner, T.; Dombret, H.; Ebert, B. L.; Fenaux, P.; Larson, R. A.; Levine, R. L.; Lo-Coco, F.; Naoe, T.; Niederwieser, D.; Ossenkoppele, G. J.; Sanz, M.; Sierra, J.; Tallman, M. S.; Tien, H. F.; Wei, A. H.; Löwenberg, B.; Bloomfield, C. D.
Article Title: Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Abstract: The first edition of the European Leuke-miaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults, published in 2010, has found broad acceptance by physicians and investigators caring for patients with AML. Recent advances, for example, in the discovery of the genomic landscape of the disease, in the development of assays for genetic testing and for detecting minimal residual disease (MRD), as well as in the development of novel antileukemic agents, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. The recommendations include a revised version of the ELN genetic categories, a proposal for a response category based on MRD status, and criteria for progressive disease. © 2017 by The American Society of Hematology.
Journal Title: Blood
Volume: 129
Issue: 4
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-01-26
Start Page: 424
End Page: 447
Language: English
DOI: 10.1182/blood-2016-08-733196
PROVIDER: scopus
PMCID: PMC5291965
PUBMED: 27895058
DOI/URL:
Notes: Review -- Export Date: 3 April 2017 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Martin Stuart Tallman
    649 Tallman
  2. Ross Levine
    775 Levine